Welcome to the e-CCO Library!

P553 Safety of the sequential use of biological therapy in inflammatory bowel disease: Results from a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Moens1,2, V. Ballet1, J. Sabino1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 30 January 2020, 10:12 AM
P553: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ghosh, S.(1)*;Long, M.(2);Ott, E.(3);Gasink, C.(3);Baker, T.(4);Godwin, B.(3);Miao, Y.(4);Loftus, E.(5);
Created: Friday, 14 July 2023, 11:05 AM
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Berger1*, A. Pilch1, J. Ruppert1, F.-P. Armbruster1, J. Stein2,3, K. Farrag2,3

Created: Thursday, 21 February 2019, 9:14 AM
P553: Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ferreiro-Iglesias*1, A. Jardi1, A. Quiroga1, I. Baston1, J. Gonzalez2, J. M. Giraldez2, I. Zarra2, M. J. Lamas2, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

Created: Friday, 22 February 2019, 9:41 AM
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Barkan, R.(1); Shpoker , L.(2);Abboud, R.(2);Nafrin, S.(3);Ganon , M.(4);Ilsar , T.(4);Volf , T.(5);Markovitch , L.(6);Saban , M.(7);Kagan, I.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Banayan E., Zagihyan K., Fleshner P.

Created: Wednesday, 20 February 2019, 10:36 AM
P554 Dietary practices and beliefs of patients with inactive ulcerative colitis: A prospective UK study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

Created: Thursday, 30 January 2020, 10:12 AM
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?
Year: 2021
Source: ECCO'21 Virtual
Authors: SinaDr., M.(1);Pemaj, X.(1);Akshija, I.(2);Hysa, A.(1);Koçollari, A.(1);Prifti, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P554: Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Higgins, P.D.R.(2);Peyrin-Biroulet, L.(3);Sands, B.E.(4);Lee, S.(5);Moses, R.E.(6);Redondo, I.(7)*;Escobar, R.(8);Morris, N.(9);Kobayashi, T.(10);
Created: Friday, 14 July 2023, 11:05 AM
P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Atreja A., Khan S., Otobo E., Rogers J., Ullman T., Grinspan A., Itzkowitz S., Maser E., Cohen B., Colombel J.-F., Sands B.

Created: Wednesday, 20 February 2019, 10:36 AM
P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Palaparthy1*, S. Schmitt2, M.I. Rehman3, C.-H. Cai1, K. Wang1, O. von Richter2

Created: Thursday, 21 February 2019, 9:14 AM
P554: Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Atreya1, H. Schmitt1, S. Fischer1, M. F. Neurath1, X. Rekalde2, D. Nagore*2, A. Ametzazurra2

Created: Friday, 22 February 2019, 9:41 AM
P554: Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study
Year: 2022
Source: ECCO'22
Authors: Lim, S.(1);Gros Alcade, B.(2);Lehmann, A.(3);Lindsay, J.(3);Gaya, D.(4);Caulfield, L.(4);Dhar, A.(5);Ritchie, S.(5);Limdi, J.(6);Taylor, J.(6);Raine, T.(7);Balendran, K.(7);Shuttleworth, E.(8);Kwok, J.(8);Cococcia, S.(9);Murray, C.(9);Walker, G.(10);Aldridge, R.(10);George, B.(10);Colbert, R.(4);Dawson, P.(1);Jameson, E.(1);Irving, P.(1);Sharma, E.(1);Lees, C.(2);Samaa, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P555 Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Gordon, J. Murray, F. Tailor, S.A. Goh, J.O. Lindsay

Created: Thursday, 30 January 2020, 10:12 AM
P555: Coagulation disorders in a population of patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Pinho1*, F. Pires1, D. Martins1, P. Sousa1, E. Cancela1, M. Farinha2, A. Silva1, P. Ministro1

Created: Thursday, 21 February 2019, 9:14 AM
P555: Deep remission and mucosal healing in IBD patients under immunosuppression with azathioprine and 6-mercaptopurine
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P555: Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Nascimento, C.(1);Revés, J.(1);Morão, B.(1);Frias Gomes, C.(1);Gouveia, C.(1);Palmela, C.(1);Roque Ramos, L.(1);Fidalgo, C.(1);Cravo, M.(1);Glória, L.(1);Torres, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Norton C.1, Czuber-Dochan W.2, Artom M.2, Sweeney L.*2, Hart A.3

Created: Wednesday, 20 February 2019, 10:36 AM
P555: Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Grimsdottir, S.(1);Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Seidelin, J.B.(1);
Created: Friday, 14 July 2023, 11:05 AM